drugset / Trial / NCT06401343
Use of SGLT2i in noHCM With HFpEF
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of nonobstructive HCM patients with HFpEF.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2024-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | — |